These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 745018)
1. L-deprenyl treatment of on-off phenomena in Parkinson's disease. Rinne UK; Siirtola T; Sonninen V J Neural Transm; 1978; 43(3-4):253-62. PubMed ID: 745018 [No Abstract] [Full Text] [Related]
2. L-deprenyl in the treatment of Parkinson's disease. Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993 [TBL] [Abstract][Full Text] [Related]
3. (-)Deprenyl in the treatment of decompensated Parkinson's disease. Csanda E; Tárczy M; Takáts A J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259 [TBL] [Abstract][Full Text] [Related]
4. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Birkmayer W; Knoll J; Riederer P; Youdim MB Mod Probl Pharmacopsychiatry; 1983; 19():170-6. PubMed ID: 6408405 [No Abstract] [Full Text] [Related]
5. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. Csanda E; Tárczy M Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143 [TBL] [Abstract][Full Text] [Related]
6. Deprenyl (selegiline) in combination treatment of Parkinson's disease. Gerstenbrand F; Ransmayr G; Poewe W Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144 [TBL] [Abstract][Full Text] [Related]
7. Long term treatment with L-deprenyl. Birkmayer W J Neural Transm; 1978; 43(3-4):239-44. PubMed ID: 745016 [No Abstract] [Full Text] [Related]
8. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid. Przuntek H; Kuhn W; Kraus P Acta Neurol Scand Suppl; 1989; 126():153-6. PubMed ID: 2482649 [TBL] [Abstract][Full Text] [Related]
9. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience. Birkmayer W; Birkmayer GD J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256 [TBL] [Abstract][Full Text] [Related]
10. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. Przuntek H; Kuhn W J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607 [TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. Siirtola T; Sonninen V; Rinne UK Clin Neurol Neurosurg; 1975; 78(2):77-88. PubMed ID: 1222507 [TBL] [Abstract][Full Text] [Related]
12. Deprenyl (selegiline) in the treatment of Parkinson's disease. Rinne UK Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141 [TBL] [Abstract][Full Text] [Related]
13. (-)Deprenyl in the treatment of Parkinson's disease. Birkmayer W; Riederer P; Youdim MB Clin Neuropharmacol; 1982; 5(2):195-230. PubMed ID: 6814755 [No Abstract] [Full Text] [Related]
15. Deprenyl (selegiline) in the treatment of Parkinson's disease. Birkmayer W Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140 [TBL] [Abstract][Full Text] [Related]
16. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease. Rinne UK J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601 [TBL] [Abstract][Full Text] [Related]
17. Experiences with L-deprenyl in Parkinsonism. Csanda E; Antal J; Antóny M; Csanaky A J Neural Transm; 1978; 43(3-4):263-9. PubMed ID: 370348 [TBL] [Abstract][Full Text] [Related]
19. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. Presthus J; Hajba A Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145 [TBL] [Abstract][Full Text] [Related]